Regenxbio: On The Cusp Of Becoming A Commercial Gene Therapy Player

Partnered with AbbVie on a wet AMD gene therapy, Regenxbio is also advancing wholly owned candidates for Duchenne muscular dystrophy and MPS I and MPS II.

Regenxbio
Regenxbio is nearing market with two AAV gene therapies • Source: Scrip/Joseph Haas

With proof of concept for its NAV platform from two gene therapy products partners have brought to the market, two products slated for regulatory submission in the next two years, and a new manufacturing facility, Regenxbio Inc. is poised to take the next step to becoming a fully realized commercial biotech, CEO Kenneth Mills told Scrip in a recent interview.

The progress is all part of the Rockville, MD-based biotech’s “5x25” strategy to bring five gene therapy candidates either to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies